Disorders of the Nervous System

Agmatine Alleviates Cisplatin-Induced Ototoxicity by Activating PI3K/AKT Signaling Pathway

Ying Zhang, Zhe Lv, and Qiang He

https://doi.org/10.1523/ENEURO.0434-21.2022

Department of Otolaryngology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China

Abstract
Cisplatin-induced ototoxicity can be partially attributed to excessive reactive oxygen species (ROS) production, and agmatine is well-known for the activation of the phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) pathway to inhibit ROS production. Whether agmatine could be used to alleviate cisplatin-induced ototoxicity is investigated. Cisplatin-exposed House Ear Institute-Organ of Corti 1 (HEI-OC1) cells and cochlear explants showed increased ROS production detected by 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) staining and decreased cell viability detected by Cell Counting Kit-8 (CCK-8) or Myosin 7a staining, which could be reversed by the agmatine pretreatment. Cisplatin intraperitoneally injected C57BL/6 mice demonstrated damaged auditory function as indicated by distortion products otoacoustic emissions (DPOAEs) and auditory brainstem response (ABR) assays, and trans-tympanically administrated agmatine in the left ears could partly prevent the auditory function loss. Mechanistically, downregulated B-cell lymphoma 2 (Bcl-2) expression, upregulated Bcl2-associated x (Bax) expression, and diminished p-PI3K and p-AKT expression were detected in cisplatin-exposed HEI-OC1 cells and cochlear explants, which could be prevented by the pretreatment with agmatine. Our investigation demonstrates that agmatine pretreatment could alleviate cisplatin-induced ototoxicity with the activation of PI3K/AKT signaling pathway.

Key words: agmatine; cisplatin-induced ototoxicity; PI3K/AKT

Significance Statement
The study demonstrated that agmatine pretreatment could activate phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) signaling pathway to alleviate cisplatin-induced ototoxicity.

Introduction
Cisplatin was approved in 1978 by the United States Food and Drug Administration (FDA) to treat ovarian cancer and metastatic testicular patients (Farrell, 2015). Although serious side effects such as bone marrow depression, nephrotoxicity, and ototoxicity can occur, cisplatin remains the most widely used and available chemotherapeutic drug to treat solid malignant tumors (Glynne-Jones and Hoskin, 2007; Chang and Chinosornvatana, 2010; Johnstone et al., 2016; Rottenberg et al., 2021). The incidence of cisplatin-induced ototoxicity can range from twenty percent to seventy percent, which may manifest with progressive, irreversible, and bilateral hearing loss (Tang et al., 2021). Young children are more inclined to cisplatin-induced ototoxicity with delayed speech development and psychosocial and cognitive development (Knight et al., 2005; Rybak et al., 2019).
It is generally believed that cisplatin-induced ototoxicity may be attributed to the excessive reactive oxygen species (ROS) production by the cochlea (Yu et al., 2020), and endoplasmic reticulum stress is a target for treatment of hearing loss (Wang and Xu, 2020). Multiple promising strategies have been performed to alleviate, treat, and prevent cisplatin-induced ototoxicity, and none of these strategies has been confirmed or recommended by the FDA (Gentilin et al., 2019; Mukherjea et al., 2020).

Among the multiple signaling pathways contributing to the survival and differentiation of hair cells, phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) pathway is the crucial pathway for the survival and differentiation of hair cells, phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) pathway. It is essential for inner ear hair cells survival to resistance against harmful stimuli (He et al., 2021). It is worth noting that, in neonatal cochlear spiral ganglion explants, PI3K/AKT signaling mediates brain-derived neurotrophic factor-induced neurite formation (Mullen et al., 2012). In the noise-induced cochlea injury, PI3K/AKT pathway activation induced by deferoxamine may promote mesenchymal stem cell homing (Peyvandi et al., 2018).

Agmatine is formed by L-arginine decarboxylation and hydrolyzation to putrescine, which can bind to NMDA receptors and α2-adrenergic receptors to function as novel neurotransmitters and neuromodulators (Regunathan, 2006; Piletz et al., 2013). Substantial preclinical and initial clinical evidence has indicated the possibility to treat opioid addiction, mood disorders, neurotrauma, neurodegenerative diseases, and cognitive disorders (Xu et al., 2018; Akasaka and Fujiiwa, 2020).

This investigation utilizes agmatine to treat cisplatin-exposed House Ear Institute-Organ of Corti 1 (HEI-OC1) cells, cochlear explants, or cisplatin affected mice and finds that agmatine alleviates hearing loss with reduced ROS production and cell loss and upregulated PI3K/AKT signal pathway. Therefore, as an adjuvant drug, agmatine has the potential value in reducing ototoxicity caused by cisplatin chemotherapy.

Materials and Methods

Cell viability
HEI-OC1 cells (5000/well) were seeded in 96-well plates in three replicates, and relevant agmatine (10, 50, 100, 200 μM) and or cisplatin (5, 10, 30, 50 μM) were incubated for indicated hours. Cell Counting Kit-8 (CCK-8; Dojindo Laboratories) was added to each well with the final concentration of 10% for 4 h. The optical density values were measured at 450 nm with a Bio-Rad plate reader.

Cisplatin-exposed HEI-OC1 cells culture
HEI-OC1 cell line was pretreated with 100 μM agmatine for 2 h and then cotreated with 30 μM cisplatin for 24 h in appropriate conditions (33°C, 5% CO₂, high-glucose DMEM, 5% fetal bovine serum, Invitrogen).

ROS detection
2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) working solution (10 μM, Beyotime, S0033) was added into six-well plates and incubated the plates at 37°C for 30 min. After the incubation, the fluorescence was observed with the LEXT OLS5100 laser scanning confocal microscope.

Cisplatin-exposed cochlear explants
Cochleae from C57BL/6 mice (3 d postnatal) were dissected out and seeded intact on Cell-Tak (BD Biosciences) coated glass coverslips, which were further incubated with DMEM/F12 medium supplemented with 1× N2/B27 as recommended by the manufacturer (Invitrogen) at 37°C with 5% CO₂. Agmatine (100 μM) was used to pretreat cochlear explants for 2 h, and then cisplatin (30 μM) was added to induce the ototoxicity for 24 h.

Western blotting
HEI-OC1 or cochlea explant lysates were separated by 12% SDS-polyacrylamide gel and transferred to polyvinylidene fluoride membranes, which was further blocked with 5% nonfat dry milk and incubated with primary antibodies against GAPDH, Bcl2-associated x (Bax), Bclll, p-PI3K, p-AKT, PI3K, and AKT (Santa Cruz). Peroxidase-conjugated secondary antibody (Sigma-Aldrich, 1:1000 dilution, 2 h, at room temperature) was added, and an ECL system (Sigma-Aldrich) was used to obtain the signal. The intensity of protein bands was quantified with ImageJ software. GAPDH was used as the loading control to normalize the relative expression.

Cisplatin-exposed mice
C57BL/6 male mice (four-week-old) purchased from Peking Vital River Laboratory Animal Ltd. were maintained. Agmatine (10 μM, 5 μl) was trans-tympanically injected into the left ears, while the same volume PBS was injected into the contralateral ears. Then cisplatin (30 mg/kg) was intraperitoneally administered 2 h later. Seven days after cisplatin administration, the auditory brainstem responses (ABRs) and distortion product otoacoustic emission (DPOAE) measurements were done. All the procedure was approved by the Ethics Committee of the Second Hospital of Hebei Medical University.

ABR test
ABR assessment was performed as previously reported (McLean et al., 2021). Briefly, anesthetized mice (25 mg/kg xylazine sodium and 100 mg/kg ketamine, i.p.) were kept warm during the ABR recordings process (highest intensity of acoustic stimuli, 90 dB SPL; decrements, 5 dB SPL) at 38°C on the thermostatic heating pad. The hearing threshold at five frequencies (4, 8, 16, 24, and 32 kHz) was detected with TDT System III apparatus (Tucker Davies Technologies).

DPOAE test
DPOAE was performed as previously reported with a TDT-RZ6 system (Tucker-Davis Technologies; Li et al., 2021). Two sine wave tones with different frequencies but equal intensities (F2 = 1.2F1, F2 ranging from 4 to
40 kHz) were used with 1 s duration to elicit DPOAE. Twenty adjacent frequency bins around the distortion product frequency were averaged as the surrounding noise floor. DPOAE threshold was determined when the signal was over 5 dB SPL and over 2 SDs above the surrounding noise floor.

**Immunofluorescence**

Intact cochleae were separated from the temporal bone, which were embedded in Optimal Cutting Temperature O.C. T. medium (Richard-Allan Scientific), snap frozen in liquid nitrogen, and stored at −80°C until use. Five-micrometer sections were cut by a cryostat (Microm HM525). After being

![Figure 1](image1.png)

*Figure 1.* The viability of HEI-OC1 cells with the treatment of designed concentration of cisplatin (a), agmatine (b), and different concentration of agmatine and 30 µM cisplatin (c) for 24 h. Data were represented as mean ± SD, n = 3; *p < 0.05, **p < 0.01 compared with control group; #p < 0.05, ##p < 0.01 compared with 30 µM cisplatin only group.

![Figure 2](image2.png)

*Figure 2.* The intracellular level of ROS in HEI-OC1 cells was detected with DCFH-DA staining. a, Fluorescent images from different groups. b, Fluorescence intensity was measured with ImageJ software. Data were represented as mean ± SD, n = 3; **p < 0.01, ***p < 0.001 compared with control group; ##p < 0.01 compared with cisplatin group. Scale bar: 50 µm.
fixed with 4% paraformaldehyde for 10 min, the sections were blocked with 10% normal goat serum and permeabilized with 0.3% Triton X-100 for 2 h at room temperature. The Fast ImmunoCytoChemistry Staining kit (Protein Biotechnologies), anti-Myosin 7a antibody (Proteus Bioscience, 25-6790), and DAPI were used for hair cell detection.

Statistical analysis
The difference between groups was assessed using one or two-way ANOVA analysis before corresponding post hoc tests. The significance level was set as p-value < 0.05. All statistical analyses were performed with GraphPad Prism (GraphPad Software).

Results
Agmatine alleviates cisplatin-induced ototoxicity in HEI-OC1 cells
To optimize the dose of cisplatin, different concentrations of cisplatin (0, 5, 10, 30, or 50 μM) were used to treat HEI-OC1 cells for 24 h, and the cell viability was analyzed by CCK-8 assay. Cisplatin (at a dose >30 μM) can markedly reduce cell viability (Fig. 1a). While as to agmatine, only 200 μM agmatine could diminish the viability of HEI-OC1 cells (Fig. 1b), which indicated that the dose under 200 μM was safe. To determine the protective effect of agmatine on cisplatin-induced ototoxicity, HEI-OC1 cells were pretreated with different...
concentrations of agmatine for 2 h and then cotreated with 30 \( \mu \text{M} \) cisplatin for 24 h. A significant dose-dependent protective effect was observed, and 100 \( \mu \text{M} \) agmatine showed the maximal protective effect (Fig. 1c). These results testified that agmatine could protect HEI-OC1 cells viability on cisplatin exposure, and 100 \( \mu \text{M} \) agmatine and 30 \( \mu \text{M} \) cisplatin were chosen in the following experiment.

**Agmatine alleviates cisplatin-induced ROS in HEI-OC1 cells**

We examined ROS production with a mitochondria-specific ROS indicator, DCFH-DA, to determine whether agmatine could alleviate cellular oxidative stress. Cisplatin-induced upregulated ROS production, while the pretreatment with agmatine could diminish ROS induction (Fig. 2a,b). It was worth noting that agmatine alone could not induce the production of ROS. All of these indicated the protective effect caused by agmatine.

**Agmatine alleviates cisplatin-induced cochleae cell apoptosis in vitro with upregulated PI3K/AKT pathway**

In order to decipher the relevant pathway for apoptosis, Bcl-2 family proteins expression was detected with Western blotting in cisplatin-exposed cells. Elevated Bax (pro-apoptotic; Fig. 3a,b) and decreased B-cell lymphoma 2 (Bcl-2; anti-apoptotic; Fig. 3a,c) were observed, which could be reversed by the pretreatment of agmatine. At the same time, the upstream PI3K/AKT signaling pathway molecules were detected. After cisplatin treatment, downregulated p-PI3K (Fig. 3a,d) and p-AKT expression (Fig. 3a,e) were detected. As expected, agmatine administration could upregulate the PI3K/AKT pathway as indicated by the upregulation of p-PI3K and p-AKT. These data demonstrated that agmatine had the ability to inhibit cisplatin-induced apoptosis with upregulated PI3K/AKT signaling pathway in HEI-OC1 cells.

**Agmatine alleviates cisplatin-induced cochleae explants apoptosis**

Myosin 7a staining showed that cisplatin treatment could lead to the conspicuous loss of mature hair cells in the apex (data not shown), basal turns (data not shown), and the middle turn of cochleae. The most significant damage effect was observed on the middle turn of the cochlea, which could be alleviated by the pretreatment of agmatine (Fig. 4a,b). Accumulation of ROS may lead to the apoptosis of hair cells. No DCFH-DA-positive cells were detected in the untreated or the agmatine-treated cochlear explants (Fig. 4c). While significantly increased DCFH-DA-positive cells were...
detected after cisplatin exposure, this increase was reversed by agmatine pretreatment (Fig. 4c,d).

Agmatine stimulates PI3K/AKT signaling to inhibit the apoptosis in cochlea explant induced by cisplatin exposure

Cochlea explant was further used to confirm the apoptosis induced by cisplatin exposure. Increased Bax expression (pro-apoptotic; Fig. 5a,b) and decreased Bcl-2 expression (anti-apoptotic; Fig. 5a,c) were observed in cisplatin-exposed cochlea explant, which could be reversed by the agmatine pretreatment. At the same time, downregulated p-PI3K (Fig. 5a,d) and p-AKT expression (Fig. 5a,e) were detected after cisplatin treatment. As expected, agmatine administration could upregulate the PI3K/AKT pathway. All of these data confirmed that agmatine could stimulate PI3K/AKT signaling pathway to inhibit cisplatin-induced intrinsic apoptosis pathway in cochlea explant and HEI-OC1 cells.

Figure 5. Effect of agmatine on the Bcl-2 family proteins expression and PI3K/AKT signaling pathway activation in the middle turns of the cochlea explant. Representative Western blot images (a) and quantitative analysis of Bax (b), Bcl-2 (c), p-PI3K (d), and p-AKT (e). Data were represented as mean ± SD, n = 3; **p < 0.01, ***p < 0.001 compared with control group; ##p < 0.01, ###p < 0.001 compared with cisplatin group.

Figure 6. Agmatine prevents auditory function loss in cisplatin-exposed mice. ABR (a) and DPOAE (b) thresholds were analyzed. Data were represented as mean ± SD, n = 6 for each group; *p < 0.05, **p < 0.01 compared with control group; #p < 0.05 compared with cisplatin group.
Agmatine prevents auditory function loss in cisplatin-exposed mice

ABR and DPOAE measurements were used to indicate the auditory function. Hearing thresholds were significantly elevated at all frequencies tested 14 d after cisplatin exposure, whereas pretreatment with agmatine could diminish the thresholds (Fig. 6a,b). All of these indicated that agmatine could partially prevent auditory function loss in cisplatin-exposed mice.

Discussion

In order to minimize cisplatin-induced ototoxicity, it is vital to find an appropriate strategy to prevent auditory function loss or restore auditory function (Tang et al., 2021). Cisplatin-exposed HEI-OC1 cells, cochlea explant, and mice are used in this investigation, and we confirm that agmatine alleviates cisplatin-induced ototoxicity with upregulated PI3K/AKT signaling pathway. Agmatine supplement may help to reduce cisplatin-induced ototoxicity in clinic.

Cisplatin can transport into cochlea cells and retain for months to years under hydrolysis to form highly reactive aqua cisplatin complexes, which can induce hair cells apoptosis, inflammation, and permanent hearing loss (Rybak et al., 2019). Our results demonstrate the beneficial effect of agmatine pretreatment on cisplatin-induced cochlea cells apoptosis with the inhibition of the downstream mitochondrial apoptotic pathway, thereby protecting cochlea cells from cisplatin-induced ototoxicity in the acute phase. A long-term effect of agmatine administration should be performed in future investigations.

Cisplatin-induced ototoxicity usually appears in the early stages after exposure to cisplatin, primarily affecting the high frequencies and leading to progressive, permanent, and cumulative hearing loss. As indicated in previous reports, DPOAE (Breglio et al., 2017) and ABR (Rybak et al., 2000) are disregulated in cisplatin-affected mice. Our investigation testifies that agmatine could improve the degenerative auditory responses ranging from 4 and 32 kHz.

Multiple intracellular signaling pathways, including PI3K/AKT pathway, can phosphorylate Bad (serine-136) to inhibit apoptosis (Wang and Youle, 2009; Lu and Imlay, 2021; Muri and Kopf, 2021). Our present study demonstrates that agmatine could increase phosphorylation of PI3K and AKT diminished by cisplatin exposure. The activation of PI3K/AKT may contribute to the anti-ototoxicity effect of agmatine on cisplatin exposure.

The antioxidant effect of agmatine may act as a scavenger against ROS in human neuronal-like SH-SY5Y cells to maintain mitochondrial membrane potential (Condello et al., 2011). In RAW 264.7 cells, agmatine has antioxidant activity against lipopolysaccharides-induced ROS accumulation via the activation of PI3K/Akt pathway (Chai et al., 2016). It is worth noting that agmatine has anti-inflammatory effects, effectively inhibiting the transcription factor NF-κB (Li et al., 2020). As to the safe dose identified in our study (200 μM agmatine), a preprint paper indicates that the safe dose of agmatine can reach to 10 mM (Park et al., 2020). Such discrepancy may need further detailed analysis.

In summation, we demonstrate that agmatine significantly affects the protection against cisplatin-induced ototoxicity by inhibiting ROS production and mitochondrial apoptosis. Our findings further indicate that agmatine can function as a therapeutic or preventive agent in cisplatin-induced ototoxicity.

In conclusion, agmatine can be used to alleviate cisplatin-induced ototoxicity with upregulated PI3K/AKT signaling.

References

Akasaka N, Fujiwara S (2020) The therapeutic and nutraceutical potential of agmatine, and its enhanced production using Aspergillus oryzae. Amino Acids 52:181–197.

Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, Hall MD, Amabile L, Cunningham LL (2017) Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun 8:1654.

Chai J, Luo L, Hou F, Fan X, Yu J, Ma W, Tang W, Yang X, Zhu J, Kang W, Yan J, Liang H (2016) Agmatine reduces lipopolysaccharide-mediated oxidant response via activating PI3K/Akt pathway and up-regulating Nrf2 and HO-1 expression in macrophages. PLoS One 11:e0163634.

Chang KW, Chinosornvatana N (2010) Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 28:1788–1795.

Condello S, Currò M, Ferlazzo N, Caccamo D, Satriano J, Jentile R (2011) Agmatine effects on mitochondrial membrane potential and NF-κB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells. J Neurochem 116:67–75.

Farrell NP (2015) Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets. Chem Soc Rev 44:8773–8785.

Gentilin E, Simon E, Candito M, Cazzador D, Astolfi L (2019) Cisplatin-induced ototoxicity: updates on molecular targets. Trends Mol Med 25:1123–1132.

Glynnne-Jones R, Hoskin P (2007) Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm? J Clin Oncol 25:5281–5286.

He Y, Zheng Z, Liu C, Li W, Zhao L, Nie G, Li H (2021) Inhibiting DNA methylation alleviates cisplatin-induced hearing loss by decreasing oxidative stress-induced mitochondria-dependent apoptosis via the LRP1–PI3K/AKT pathway. Acta Pharm Sin B, in Press.

Johnstone TC, Suntharalingam K, Lppard SJ (2016) The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 116:3436–3486.

Knight KR, Kraemer DF, Neuwell EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588–8596.

Li X, Zhu J, Tian L, Ma X, Fan X, Luo L, Yu J, Sun Y, Yang X, Tang W, Ma W, Yan J, Xu X, Liang H (2020) Agmatine protects against the progression of sepsis through the imidazoline I2 receptor-ribosomal S6 kinase 2-nuclear factor-κB signaling pathway. Crit Care Med 48:e40–e47.

Li Y, Zhou X, Shen X (2021) Esketamine may be an ideal substitute for ketamine during cochlear function measurement. Braz J Med Biol Res 54:e11503.

Liu Y, Wei M, Mao X, Chen T, Lin P, Wang W (2021) Key signaling pathways regulate the development and survival of auditory hair cells. Neural Plast 2021:5522717.

Lu Z, Imlay JA (2021) When anaerobes encounter oxygen: mechanisms of oxygen toxicity, tolerance and defense. Nat Rev Microbiol 19:774–785.
McLean T, Clamp P, Campbell L, Hampson A, Chambers S, Collins A, Bester C, O’Leary S (2021) The effect of different round window sealants on cochlear mechanics over time. Otol Neurotol 42:1253–1260.

Mukherjea D, Dhukhwa A, Sapra A, Bhandari P, Woolford K, Franke J, Ramkumar V, Rybak L (2020) Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity. Expert Opin Drug Metab Toxicol 16:965–982.

Mullen LM, Pak KK, Chavez E, Kondo K, Brand Y, Ryan AF (2012) Ras/p38 and PI3K/Akt but not Mek/Erk signaling mediate BDNF-induced neurite formation on neonatal cochlear spiral ganglion explants. Brain Res 1430:25–34.

Muri J, Kopf M (2021) Redox regulation of immunometabolism. Nat Rev Immunol 21:363–381.

Park E, Lee SH, Lee H, Kim YC, Jung HH, Im GJ (2020) Protective effect of agmatine against cisplatin-induced apoptosis in an auditory cell line. bioRxiv 2020.2003.2024.005314.

Peyvandi AA, Abbaszadeh HA, Roozbanhany NA, Pourbakht A, Khoshirsat S, Niri HH, Peyvandi H, Niknazar S (2018) Deferoxamine promotes mesenchymal stem cell homing in noise-induced injured cochlea through PI3K/AKT pathway. Cell Prolif 51:e12434.

Piletz JE, Acioglou F, Cheng JT, Fairbanks CA, Gilad VH, Haenisch B, Halaris A, Hong S, Lee JE, Li J, Liu P, Molderings GJ, Rodrigues AL, Satriano J, Seong GJ, Wilcox G, Wu N, Gilad GM (2013) Agmatine: clinical applications after 100 years in translation. Drug Discov Today 18:880–893.

Regunathan S (2006) Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence. Aaps j 8:E479–E484.

Rottenberg S, Disler C, Perego P (2021) The rediscovery of platinum-based cancer therapy. Nat Rev Cancer 21:37–50.

Rybak LP, Husain K, Morris C, Whitworth C, Somani S (2000) Effect of protective agents against cisplatin ototoxicity. Am J Otol 21:513–520.

Rybak LP, Mukherjea D, Ramkumar V (2019) Mechanisms of cisplatin-induced ototoxicity and prevention. Semin Hear 40:197–204.

Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, Chen Y, Zou Z (2021) Cisplatin-induced ototoxicity: updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm 163:60–71.

Wang C, Youle RJ (2009) The role of mitochondria in apoptosis*. Annu Rev Genet 43:95–118.

Wang Y, Xu Z (2020) Endoplasmic reticulum stress as target for treatment of hearing loss. STEMedicine 1:e21.

Xu W, Gao L, Li T, Shao A, Zhang J (2018) Neuroprotective role of agmatine in neurological diseases. Curr Neuropharmacol 16:1296–1305.

Yu DJ, Gu Y, Chen W, Kang X, Wang H Wu (2020) Current strategies to combat cisplatin-induced ototoxicity. Front Pharmacol 11:999.